• Narender Karra Department of Pharmaceutics, Malla Reddy Institute of Pharmaceutical Sciences, Maisammaguda, Secunderabad, Telangana, India.
  • Narayana Raju P Department of Pharmaceutical Chemistry, Geethanjali College of Pharmacy, Cheeryal, Telangana, India.
  • Sivakumar R Department of Pharmaceutical Chemistry, Geethanjali College of Pharmacy, Cheeryal, Telangana, India.


Objective: The objective of this study was to develop extended release (ER) pellets of Bosentan, an endothelin receptor antagonist using fluid bed processor (coating).

Method: The ER drug pellets of Bosentan were prepared using fluid bed coating. These drug-loaded pellets were further coated with ethyl cellulose of two viscosity grades and Eudragit as rate controlling polymers individual and in combination, hypromellose as pore former and binder, acetyl tributyl citrate as plasticizer, and magnesium stearate as anti-adhering agent.

Results: The drug release was extended up to 24 h, and the drug release was mainly depends on the polymer type and polymer proportion. In vivo study of Bosentan, ER pellets were performed in healthy rabbits (New Zealand, White) of either sex weighing (3.0–3.3 kg) and were divided into two separate groups, each group consisting of 6 animals. Maximum plasma concentration (Cmax), maximum time (Tmax), area under the curve (AUC0-t), elimination rate constant (Kel), and half-life (T1/2) were studied for optimized formulation. Formulation was releasing the drug for a prolonged period of time.

Conclusion: By the above results, it was observed that the prepared pellets could release the drug for an extended period when compared with the conventional dosage form of Bosentan, optimized formulation was shown longer half-life and Cmax indicates its acceptability. Finally, ER pellets of Bosentan were prepared for the treatment of pulmonary artery hypertension by fluid bed processor.

Keywords: Bosentan, Pellets, EC, Eudragits, Prolonged release pellets.


1. Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 2002;5:82-5.
2. Katteboinaa S, Chandrasekhar PV, Balaji S. Drug nanocrystals: A novel formulation approach for poorly soluble drugs. Int J PharmTech Res 2009;1:682-94.
3. Prasad MB, Vidyadhara S, Trilochani P. Development and evaluation of diltiazem hydrochloride controlled-release pellets by fluid bed coating process. J Pharm Technol Res 2013;4:101-7.
4. Jyothi BJ, Doniparthy J. Multiparticulate drug delivery systems using natural polymers as release retardant materials. Int J Pharm Pharm Sci 2014;6:61-5.
5. Baramade MK, Patwekar SL. Controlled release approach to novel multiparticulate drug delivery systems. Int J Pharm Pharm Sci 2012;4:757-63.
6. Gajdos B. Rotary granulators-evaluation of process technology for pellet production using factorial design. Drugs Made Ger 1984;27:10-6.
7. Kristensen HG, Schaefer T, Granulation. A review of pharmaceutical wet granulation. Drug Dev Ind Pharm 1987;13:803-72.
8. Ghebre-Sellassie I. Pellets: A General overview in Pharmaceutical Pelletization Technology. Vol. 37. New York, USA: Marcel Dekker, Inc.; 1989. p. 1-13.
9. Ghebre SI, Gordon R, Fawzi MB, Nesbitt RU. Evaluation of a high-speed pelletization process and equipment. Drug Dev Ind Pharm 1985;11:1523-41.
10. Moorthy KS, Kumar KP. Studies on formulation and evaluation of ethylcellulose based extended release metformin hydrochloride matrix tablets. Asian J Pharm Clin Res 2016;9:309-15.
11. Rao KR, Senapathi P, Das MK. Formulation and in vitro evaluation of ethyl cellulose microspheres containing zidovudine. J Microcapsul 2005;22:863-76.
12. Kumar KP, Bhowmik D, Dutta A, Paswan S, Deb L. Recent trends in scope and opportunities of control release oral drug delivery systems. Crit Rev Pharm Sci 2012;1:20-33.
13. Arafat M. Approaches to achieve an oral controlled release drug delivery system using polymers: A recent review. Int J Pharm Pharm Sci 2015;7:16-21.
14. Holm P, Liska J, Clozel Ml. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg 1996;11:890-7.
15. Maryandele J, O’Neil, Smith A, Patricia E, Heckelman, Susan B. The Merck Index. 30th ed. White House Station, NJ: Merck Research Laboratories; 2001.
16. Sweetman SC. Matrindale-the Complete Drug Reference. 34th ed. London: Pharmaceutical Press; 2002.
17. Langtry HD, Benfield P. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential drugs. Pub Med 1990;40:291-313.
18. Thoma K, Ziegler I. The PH independent release of fenoldopam from pellets with insoluble film coats. Eur J Pharm Biopharm 1998;46:105 13.
19. Shivakumar HN, desai BG, Sarasija S. Design and evaluation of pH sensitive multiparticulate systems for chronotherapeutic delivery of diltiazem hydrochloride. Ind J Pharm Sci 2006;68:781-7.
20. Gangurde HH, Chordiya MA, Tamizharasi S, Sivakumar T. Statistical optimization of mesalamine coated pellets for possible ileo–ceacal targeting. Mahidol Univ J Pharm Sci 2013;40:25-44.
21. Tubati VP, Murthy TE, Rao AS. Formulation development and statistical optimization of ivabradine hydrochloride floating pulsatile pellets by fluidized bed coating technique. Asian J Pharm Clin Res 2016;9:159-66.
119 Views | 216 Downloads
How to Cite
Karra, N., N. R. P, and S. R. “FORMULATION AND IN VITRO IN VIVO EVALUATION OF BOSENTAN PELLETS FOR PROLONGED DRUG RELEASE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 8, Aug. 2018, pp. 498-02, doi:10.22159/ajpcr.2018.v11i8.27833.
Original Article(s)